Publication: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
Loading...
Identifiers
Date
2017-11-13
Authors
Cassinello, J
Arranz, J A
Piulats, J M
Sanchez, A
Perez-Valderrama, B
Mellado, B
Climent, M A
Olmos, D
Carles, J
Lazaro, M
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Metrics
Export
Abstract
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma.
Description
MeSH Terms
Antineoplastic Agents
Humans
Male
Prostatic Neoplasms
Humans
Male
Prostatic Neoplasms
DeCS Terms
Docetaxel
Neoplasias de la Próstata
Castración
Próstata
Neoplasias de la Próstata
Castración
Próstata
CIE Terms
Keywords
Abiraterone, Androgen deprivation treatment, Cabazitaxel, Castration-resistant prostate cancer, Docetaxel, Enzalutamide, Hormone-sensitive advanced prostate cancer, Radium 223
Citation
Cassinello J, Arranz JÁ, Piulats JM, Sánchez A, Pérez-Valderrama B, Mellado B, et al. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). Clin Transl Oncol. 2018 Jan;20(1):57-68